The cost-effectiveness of long-term post-treatment peer recovery support services in the United States.

IF 2.7 3区 医学 Q2 PSYCHOLOGY, CLINICAL
Sierra Castedo de Martell, Margaret Brannon Moore, Hannah Wang, Lori Holleran Steiker, J Michael Wilkerson, Nalini Ranjit, Sheryl A McCurdy, H Shelton Brown
{"title":"The cost-effectiveness of long-term post-treatment peer recovery support services in the United States.","authors":"Sierra Castedo de Martell, Margaret Brannon Moore, Hannah Wang, Lori Holleran Steiker, J Michael Wilkerson, Nalini Ranjit, Sheryl A McCurdy, H Shelton Brown","doi":"10.1080/00952990.2024.2406251","DOIUrl":null,"url":null,"abstract":"<p><p><i>Background:</i> Peer recovery support services (PRSS) have been widely adopted across a variety of settings, but little is known about their economic impact.<i>Objectives:</i> To conduct a cost-effectiveness analysis of long-term, PRSS delivered after specialty substance use disorder (SUD) treatment (post-treatment), and to describe the development of a free, web-based cost-effectiveness calculator based on this analysis.<i>Methods:</i> Using publicly available data from a variety of sources, post-treatment PRSS were compared to specialty SUD treatment from the societal (broad perspective including costs like participant time) and health systems perspectives (only costs borne by health system), and in terms of quality-adjusted life years (QALYs) added and people in recovery. Whenever possible, 2019 data were used to avoid the impacts of COVID-19. Standard willingness-to-pay thresholds and additional treatment episode cost ($17,203.74) were used. One-way and probabilistic sensitivity analyses were conducted. Two recovery community organizations (RCOs) were involved in model refinement and calculator development in 2022.<i>Results:</i> Post-treatment PRSS were cost-effective to all thresholds and perspectives: $5,898.60 per QALY and $10,562.08 per person in recovery from the health system perspective, and $3,421.58 per QALY and $6,126.72 per person in recovery from the societal perspective, and post-treatment PRSS remained cost-effective across a variety of conditions in the sensitivity analyses. A cost-effectiveness calculator was developed from the analysis and is available at https://go.uth.edu/cea.<i>Conclusions:</i> In light of finding PRSS cost-effective, the expansion of PRSS across the US should continue, and may be aided by using the cost-effectiveness calculator to estimate tailored results for a specific program.</p>","PeriodicalId":48957,"journal":{"name":"American Journal of Drug and Alcohol Abuse","volume":" ","pages":"1-11"},"PeriodicalIF":2.7000,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Drug and Alcohol Abuse","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/00952990.2024.2406251","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PSYCHOLOGY, CLINICAL","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Peer recovery support services (PRSS) have been widely adopted across a variety of settings, but little is known about their economic impact.Objectives: To conduct a cost-effectiveness analysis of long-term, PRSS delivered after specialty substance use disorder (SUD) treatment (post-treatment), and to describe the development of a free, web-based cost-effectiveness calculator based on this analysis.Methods: Using publicly available data from a variety of sources, post-treatment PRSS were compared to specialty SUD treatment from the societal (broad perspective including costs like participant time) and health systems perspectives (only costs borne by health system), and in terms of quality-adjusted life years (QALYs) added and people in recovery. Whenever possible, 2019 data were used to avoid the impacts of COVID-19. Standard willingness-to-pay thresholds and additional treatment episode cost ($17,203.74) were used. One-way and probabilistic sensitivity analyses were conducted. Two recovery community organizations (RCOs) were involved in model refinement and calculator development in 2022.Results: Post-treatment PRSS were cost-effective to all thresholds and perspectives: $5,898.60 per QALY and $10,562.08 per person in recovery from the health system perspective, and $3,421.58 per QALY and $6,126.72 per person in recovery from the societal perspective, and post-treatment PRSS remained cost-effective across a variety of conditions in the sensitivity analyses. A cost-effectiveness calculator was developed from the analysis and is available at https://go.uth.edu/cea.Conclusions: In light of finding PRSS cost-effective, the expansion of PRSS across the US should continue, and may be aided by using the cost-effectiveness calculator to estimate tailored results for a specific program.

背景:同伴康复支持服务(PRSS)已在各种环境中被广泛采用,但人们对其经济影响却知之甚少:对专业药物使用障碍(SUD)治疗(治疗后)后提供的长期同伴康复支持服务(PRSS)进行成本效益分析,并介绍在此分析基础上开发的基于网络的免费成本效益计算器:利用各种来源的公开数据,从社会角度(包括参与者时间等成本在内的广义角度)和医疗系统角度(仅包括医疗系统承担的成本),以及从增加的质量调整生命年 (QALY) 和康复人数的角度,对治疗后 PRSS 与专业药物使用障碍治疗进行了比较。尽可能使用 2019 年的数据,以避免 COVID-19 的影响。使用了标准的支付意愿阈值和额外治疗费用(17,203.74 美元)。进行了单向和概率敏感性分析。2022 年,两个康复社区组织(RCO)参与了模型完善和计算器开发:治疗后 PRSS 在所有阈值和视角下都具有成本效益:从卫生系统的角度来看,每 QALY 5,898.60 美元,每个康复者 10,562.08 美元;从社会的角度来看,每 QALY 3,421.58 美元,每个康复者 6,126.72 美元。根据分析结果开发了成本效益计算器,可在 https://go.uth.edu/cea.Conclusions 网站上查阅:鉴于 PRSS 具有成本效益,应继续在全美推广 PRSS,并可使用成本效益计算器估算特定计划的定制结果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
4.70
自引率
3.70%
发文量
68
期刊介绍: The American Journal of Drug and Alcohol Abuse (AJDAA) is an international journal published six times per year and provides an important and stimulating venue for the exchange of ideas between the researchers working in diverse areas, including public policy, epidemiology, neurobiology, and the treatment of addictive disorders. AJDAA includes a wide range of translational research, covering preclinical and clinical aspects of the field. AJDAA covers these topics with focused data presentations and authoritative reviews of timely developments in our field. Manuscripts exploring addictions other than substance use disorders are encouraged. Reviews and Perspectives of emerging fields are given priority consideration. Areas of particular interest include: public health policy; novel research methodologies; human and animal pharmacology; human translational studies, including neuroimaging; pharmacological and behavioral treatments; new modalities of care; molecular and family genetic studies; medicinal use of substances traditionally considered substances of abuse.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信